Literature DB >> 10404216

Solution structure of core binding factor beta and map of the CBF alpha binding site.

X Huang1, J W Peng, N A Speck, J H Bushweller.   

Abstract

The core binding factor beta subunit (CBF beta) is the non-DNA binding subunit of the core-binding factors, transcription factors essential for multiple developmental processes including hematopoiesis and bone development. Chromosomal translocations involving the human CBFB gene are associated with a large percentage of human leukemias. The N-terminal 141 amino acids of CBF beta contains the heterodimerization domain for the DNA-binding CBF alpha subunits, and is sufficient for CBF beta function in vivo. Here we present the high-resolution solution structure of the CBF beta heterodimerization domain. It is a novel alpha/beta structure consisting of two three-stranded beta-sheets packed on one another in a sandwich arrangement, with four peripheral alpha-helices. The CBF alpha binding site on CBF beta has been mapped by chemical shift perturbation analysis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10404216     DOI: 10.1038/10670

Source DB:  PubMed          Journal:  Nat Struct Biol        ISSN: 1072-8368


  20 in total

1.  HIV type 1 viral infectivity factor and the RUNX transcription factors interact with core binding factor β on genetically distinct surfaces.

Authors:  Judd F Hultquist; Rebecca M McDougle; Brett D Anderson; Reuben S Harris
Journal:  AIDS Res Hum Retroviruses       Date:  2012-08-13       Impact factor: 2.205

2.  Auto-inhibition and partner proteins, core-binding factor beta (CBFbeta) and Ets-1, modulate DNA binding by CBFalpha2 (AML1).

Authors:  T L Gu; T L Goetz; B J Graves; N A Speck
Journal:  Mol Cell Biol       Date:  2000-01       Impact factor: 4.272

3.  Novel beta-barrel fold in the nuclear magnetic resonance structure of the replicase nonstructural protein 1 from the severe acute respiratory syndrome coronavirus.

Authors:  Marcius S Almeida; Margaret A Johnson; Torsten Herrmann; Michael Geralt; Kurt Wüthrich
Journal:  J Virol       Date:  2007-01-03       Impact factor: 5.103

4.  New insights into transcriptional and leukemogenic mechanisms of AML1-ETO and E2A fusion proteins.

Authors:  Jian Li; Chun Guo; Nickolas Steinauer; Jinsong Zhang
Journal:  Front Biol (Beijing)       Date:  2016-09-03

Review 5.  Overview of protein structural and functional folds.

Authors:  Peter D Sun; Christine E Foster; Jeffrey C Boyington
Journal:  Curr Protoc Protein Sci       Date:  2004-05

6.  Filamin A-bound PEBP2beta/CBFbeta is retained in the cytoplasm and prevented from functioning as a partner of the Runx1 transcription factor.

Authors:  Naomi Yoshida; Takehiro Ogata; Kenji Tanabe; Songhua Li; Megumi Nakazato; Kazuyoshi Kohu; Toshiro Takafuta; Sandor Shapiro; Yasutaka Ohta; Masanobu Satake; Toshio Watanabe
Journal:  Mol Cell Biol       Date:  2005-02       Impact factor: 4.272

7.  Application of the random coil index to studying protein flexibility.

Authors:  Mark V Berjanskii; David S Wishart
Journal:  J Biomol NMR       Date:  2007-11-06       Impact factor: 2.835

8.  Gene array analysis reveals a common Runx transcriptional programme controlling cell adhesion and survival.

Authors:  S Wotton; A Terry; A Kilbey; A Jenkins; P Herzyk; E Cameron; J C Neil
Journal:  Oncogene       Date:  2008-06-16       Impact factor: 9.867

9.  The RUNX1 transcription factor is expressed in serous epithelial ovarian carcinoma and contributes to cell proliferation, migration and invasion.

Authors:  Mamadou Keita; Magdalena Bachvarova; Chantale Morin; Marie Plante; Jean Gregoire; Marie-Claude Renaud; Alexandra Sebastianelli; Xuan Bich Trinh; Dimcho Bachvarov
Journal:  Cell Cycle       Date:  2013-02-26       Impact factor: 4.534

10.  CBFβ stabilizes HIV Vif to counteract APOBEC3 at the expense of RUNX1 target gene expression.

Authors:  Dong Young Kim; Eunju Kwon; Paul D Hartley; David C Crosby; Sumanjit Mann; Nevan J Krogan; John D Gross
Journal:  Mol Cell       Date:  2013-01-17       Impact factor: 17.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.